GlassScriptPhysician profile
Melissa Martz
NPI 1558724393
$2,100.50
in general payments reported to CMS, 2019-2025
28 companies · $218 in 2025
The $218 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $832 · 2022: $659 · 2023: $337 · 2024: $54.29 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $609.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $512.37 | 2021-2025 | Xtampza |
| Abbvie INC. | $470.90 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $138.54 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $104.02 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $94.99 | 2025 | Austedo Xr |
| Eisai INC. | $75.44 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $73.11 | 2021 | |
| Boston Scientific Corporation | $72.21 | 2021 | |
| Scilex Pharmaceuticals INC. | $65.73 | 2021-2023 | Ztlido |
| Alnylam Pharmaceuticals INC. | $55.05 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $41.32 | 2022 | |
| Pfizer INC. | $40.52 | 2021-2024 | |
| Ucb, INC. | $37.53 | 2025 | Rystiggo |
| Grt US Holding, INC. | $36.03 | 2022 | |
| Vanda Pharmaceuticals INC. | $31.40 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $29.89 | 2025 | Amyvid, Kisunla, Mounjaro |
| Allergan, INC. | $28.87 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.80 | 2022 | |
| Merck Sharp & Dohme LLC | $21.36 | 2022 | |
| Indivior INC. | $20.95 | 2022 | |
| Alkermes, INC. | $20.80 | 2022 | |
| Valinor Pharma, LLC | $19.93 | 2023 | Movantik |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.57 | 2025 | Relistor |
| Idorsia Pharmaceuticals US INC | $16.97 | 2022 | |
| Nalu Medical, INC. | $15.15 | 2021 | |
| Hikma Pharmaceuticals USA | $13.48 | 2022 | |
| Orexo US, INC. | $13.29 | 2021 | |
| Forte Bio-Pharma LLC | $7.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Martz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.